Pharmacokinetics in children

T½ intravasal: 4-5 hours. Note: the intravasal half-life is not the same as the biological half-life (relationship between duration of the effect and time). After 3 hours, the volume-increasing effect has decreased by 50%.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Overfilling, hypersensitivity reactions (urticaria, anaphylaxis, fever), haemodilution (extension of the bleeding time at high concentrations) and renal function disorders (at high concentrations).

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Be aware of the potential for overfilling: pulmonary oedema and congestive heart failure.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• BLOOD AND BLOOD FORMING ORGANS
• BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

BLOOD AND RELATED PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007

Changes

Therapeutic Drug Monitoring

Overdose